<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03970161</url>
  </required_header>
  <id_info>
    <org_study_id>Retinal nerve injury in T2DM</org_study_id>
    <nct_id>NCT03970161</nct_id>
  </id_info>
  <brief_title>Evaluation of Early Retinal Nerve Injury in Type 2 Diabetes Patients Without Diabetic Retinopathy</brief_title>
  <official_title>Evaluation of Early Retinal Nerve Injury in Type 2 Diabetes Patients Without Diabetic Retinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Third Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The object of this study is to investigate the damage to the retinal nerve fiber layer (RNFL)
      and ganglion cell complex layer (GCL+) in diabetic patients without retinal microangioma as
      detected by fundus fluorescein angiography (FFA) and to determine the kind of nerve damage
      more likely to indicate early injury.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with type 2 diabetes mellitus and healthy volunteers will be included in our study.
      Patients with retinal microangioma are excluded by FFA. The parameters around the optic disc
      and macular area of the above two groups are measured by optical coherence tomography (OCT),
      and the results will be analyzed using the SPSS 22.0 software.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 29, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peripapillary RNFL thickness</measure>
    <time_frame>96 weeks</time_frame>
    <description>Peripapillary RNFL thickness</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GCL+ in the macular area obtained using the 3D wide mode</measure>
    <time_frame>96 weeks</time_frame>
    <description>GCL+ in the macular area obtained using the 3D wide mode</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retinal thickness in all macular regions</measure>
    <time_frame>96 weeks</time_frame>
    <description>Retinal thickness in all macular regions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RNFL thickness in the macular area obtained using the 3D Macula (v) mode</measure>
    <time_frame>96 weeks</time_frame>
    <description>RNFL thickness in the macular area obtained using the 3D Macula (v) mode</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GCL+ thickness in the macular region obtained using the 3D Macula (v) mode</measure>
    <time_frame>96 weeks</time_frame>
    <description>GCL+ thickness in the macular region obtained using the 3D Macula (v) mode</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">720</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Diabetic Retinopathy</condition>
  <condition>Nerve Injury</condition>
  <arm_group>
    <arm_group_label>T2DM Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients without microangioma changes undergoing FFA examination were included in the present study. All of the participants enrolled in the present study underwent a systematic ophthalmic examination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy control subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All of the participants enrolled in the present study underwent a systematic ophthalmic examination.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>routine ophthalmic examination</intervention_name>
    <description>Routine ophthalmic examination, including slit lamp, intraocular pressure, and fundus examinations using direct or indirect ophthalmoscopy after pupil dilation and optical coherence tomography (OCT) examination. Patients with DM also underwent fundus fluorescein angiography (FFA) examination.</description>
    <arm_group_label>T2DM Patients</arm_group_label>
    <arm_group_label>healthy control subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with T2DM

          2. Patients without microangioma

        Exclusion Criteria:

          1. Patients with any other ocular disease that might affect retinal nerve injury

          2. Patients with optic neuropathy, age-related macular degeneration, retinal and
             choroidal disease, and retinal artery/vein occlusion.

          3. Patients with hypertension, hematopathy, neuropathy, and other systemic diseases
             causing retinal nerve changes.

          4. Patients with keratopathy, cataract, and vitreous hemorrhage were also excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiang Zhu, Dorctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Third Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiang Zhu</last_name>
    <phone>13826452564</phone>
    <email>0628zhuxiang@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The third affiliated hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiang Zhu, Doctor</last_name>
      <phone>13826452564</phone>
      <email>0628zhuxiang@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 22, 2019</study_first_submitted>
  <study_first_submitted_qc>May 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2019</study_first_posted>
  <last_update_submitted>May 29, 2019</last_update_submitted>
  <last_update_submitted_qc>May 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Third Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Xiang Zhu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

